Cetacaine Topical Anesthetic Spray and Liquid

Manufacturer
Cetylite Industries, Inc.
Effective date
2025-01-10
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
9
Source
full-release
Hydrated at
2026-05-31 21:22:55

Label at a glance#

ProductCetacaine Anesthetic
Active ingredientBenzocaine, Butamben, Tetracaine Hydrochloride
Label structure18 sections

Dosage and administration

Cetacaine Spray should be applied for approximately one second or less for normal anesthesia. Only a limited quantity of Cetacaine is required for anesthesia. Spray in excess of two seconds is contraindicated. Each one-second spray contains an average of 200 mg of product, not including propellant. To apply, insert the cannula firmly onto the protruding plastic stem on the bottle and press the cannula forward to a...

Storage and handling

Store at controlled room temperature 20-25°C (68-77°F)

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

In a bland, water-soluble base.
Active ingredients
Benzocaine14.0%
Butamben2.0%
Tetracaine Hydrochloride2.0%
Contains
Benzalkonium Chloride0.5%
Cetyl Dimethyl Ethyl Ammonium Bromide0.005%

SPL UNCLASSIFIED SECTION

Rx Only.

STORAGE AND HANDLING SECTION

Store at controlled room temperature 20-25°C (68-77°F)

Action

MECHANISM OF ACTION SECTION

The onset of Cetacaine-produced anesthesia is rapid (approximately 30 seconds) and the duration of anesthesia is typically 30-60 minutes, when used as directed. This effect is due to the rapid onset, but short duration of action of Benzocaine coupled with the slow onset, but extended duration of Tetracaine HCI and bridged by the intermediate action of Butamben.

These agents act by reversibly blocking nerve conduction. Speed and duration of action is determined by the ability of the agent to be absorbed by the mucous membrane and nerve sheath and then to diffuse out, and ultimately be metabolized (primarily by plasma cholinesterases) to inert metabolites which are excreted in the urine.

Indications

INDICATIONS & USAGE SECTION

Cetacaine is a topical anesthetic indicated for the production of anesthesia of all accessible mucous membrane except the eyes. Cetacaine Spray is indicated for use to control pain or gagging.

Cetacaine in all forms is indicated to control pain and for use for surgical or endoscopic or other procedures in the ear, nose, mouth, pharynx, larynx, trachea, bronchi, and esophagus. It may also be used for vaginal or rectal procedures when feasible.

Dosage and Administration

DOSAGE & ADMINISTRATION SECTION

SPL UNCLASSIFIED SECTION

Cetacaine Spray should be applied for approximately one second or less for normal anesthesia. Only a limited quantity of Cetacaine is required for anesthesia. Spray in excess of two seconds is contraindicated. Each one-second spray contains an average of 200 mg of product, not including propellant.

To apply, insert the cannula firmly onto the protruding plastic stem on the bottle and press the cannula forward to actuate the spray valve. The cannula may be removed and reinserted as many times as required for cleaning, or sterilization, and is autoclavable.

Cetacaine Liquid

SPL UNCLASSIFIED SECTION

Apply 200 mg liquid (approximately 0.2 mL) directly to tissue. Liquid in excess of 400 mg (approximately 0.4 mL) is contraindicated.

To apply, remove and discard the shipping cap from the bottle. Replace it with the supplied Luer-lock cap. Caution: Do not over-tighten. Remove small cap from luer-lock port, retaining it for replacement after use. Port allows for a single dip of a cotton or brush applicator for application directly to accessible mucous membrane. For application into periodontal pockets, Cetylite Luer-lock syringes and Microcapillary Delivery Tips are recommended. Cetylite Syringes are clearly marked in (4) 0.1 mL increments. To fill, attach syringe to port by gently twisting clockwise until secure. Invert and draw desired amount of liquid into the syringe. Remove filled syringe and attach Microcapillary Delivery Tip to the syringe. Tip may be bent to improve access. Apply drop-wise to accessible mucous membrane (such as buccal and lingual sulcus) by slowly depressing the syringe plunger. Discard all applicators after use.

An appropriate pediatric dosage has not been established for Cetacaine Spray or Cetacaine Liquid.

Dosages should be reduced in the debilitated elderly, acutely ill, and very young patients (i.e., children 2 years and older).

Do not use Cetacaine Spray or Cetacaine Liquid to treat infants or children younger than 2 years.

Tissue need not be dried prior to application of Cetacaine. Cetacaine should be applied directly to the site where pain control is required. Anesthesia is produced within one minute with an approximate duration of thirty minutes. Each 200 mg dose of Cetacaine (Spray or Liquid) contains 28 mg of benzocaine, 4 mg of butamben and 4 mg of tetracaine HCl.

WARNINGS AND PRECAUTIONS

WARNINGS SECTION

Methemoglobinemia

SPL UNCLASSIFIED SECTION

Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.

Signs and symptoms of methemoglobinemia may occur immediately or may be delayed some hours after exposure and are characterized by a cyanotic skin discoloration and abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue Cetacaine and any other oxidizing agents. Depending on the severity of the symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. More severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen.

DRUG INTERACTIONS

DRUG INTERACTIONS SECTION

Patients that are administered local anesthetics may be at increased risk of developing methemoglobinemia when concurrently exposed to the following oxidizing agents:

ClassExamples
Nitrates/Nitritesnitroglycerin, nitroprusside, nitric oxide, nitrous oxide
Local anestheticsbenzocaine, lidocaine, bupivacaine, mepivacaine, tetracaine, prilocaine, procaine, articaine, ropivacaine
Antineoplastic agentscyclophosphamide, flutamide, rasburicase, ifosfamide, hydroxyurea
Antibioticsdapsone, sulfonamides, nitrofurantoin, para-aminosalicylic acid
Antimalarialschloroquine, primaquine
Anticonvulsantsphenytoin, sodium valproate, phenobarbital
Other drugsacetaminophen, metoclopramide, sulfa drugs (i.e., sulfasalazine), quinine

PATIENT COUNSELING INFORMATION

INFORMATION FOR PATIENTS SECTION

Inform patients that use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly. Advise patients or caregivers to stop use and seek immediate medical attention if they or someone in their care experience the following signs or symptoms: pale, gray, or blue colored skin (cyanosis); headache; rapid heart rate; shortness of breath; lightheadedness; or fatigue.

Hypersensitivity Reactions

SPL UNCLASSIFIED SECTION

Unpredictable adverse reactions (i.e. hypersensitivity, including anaphylaxis) are extremely rare.

Localized allergic reactions may occur after prolonged or repeated use of any aminobenzoate anesthetic. The most common adverse reaction caused by local anesthetics is contact dermatitis characterized by erythema and pruritus that may progress to vesiculation and oozing. This occurs most commonly in patients following prolonged self-medication, which is contraindicated. If rash, urticaria, edema, or other manifestations of allergy develop during use, the drug should be discontinued. To minimize the possibility of a serious allergic reaction, Cetacaine preparations should not be applied for prolonged periods except under continual supervision. Dehydration of the epithelium or an escharotic effect may also result from prolonged contact.

Use in Pregnancy

PREGNANCY SECTION

Safe use of Cetacaine has not been established with respect to possible adverse effects upon fetal development. Therefore, Cetacaine should not be used during early pregnancy, unless in the judgement of a physician, the potential benefits outweigh the unknown hazards. Routine precaution for the use of any topical anesthetic should be observed when Cetacaine is used.

Contraindications

CONTRAINDICATIONS SECTION

Do not use Cetacaine Spray or Cetacaine Liquid to treat infants or children younger than 2 years.

Cetacaine is not suitable and should never be used for injection. Do not use on the eyes. To avoid excessive systemic absorption, Cetacaine should not be applied to large areas of denuded or inflamed tissue. Cetacaine should not be administered to patients who are hypersensitive to any of its ingredients or to patients known to have cholinesterase deficiencies. Tolerance may vary with the status of the patient.

Cetacaine should not be used under dentures or cotton rolls, as retention of the active ingredients under a denture or cotton roll could possibly cause an escharotic effect. Routine precaution for the use of any topical anesthetic should be observed when using Cetacaine.

Autoclavable Cannula for Cetacaine Spray

SPL UNCLASSIFIED SECTION

  • The supplied 4" stainless steel cannula for Cetacaine Spray is specially designed for accessibility and application of Cetacaine, at the required site of pain control. Replacement cannulas are available as a 10-pack (Item # 0205).

Luer-lock Syringes and Microcapillary Delivery Tips for Cetacaine Liquid

SPL UNCLASSIFIED SECTION

  • Cetacaine Liquid Syringes and Microcapillary Delivery Tips are supplied with the Cetacaine Liquid Chairside Kit (Item # 0218) and Clinical Kit (Item # 0212). They also can be purchased separately. Syringes are available in packs of 50 (Item # 0219S) or packs of 100 (Item # 0214). Delivery Tips are available in packs of 50 (Item # 0219T) or packs of 100 (Item # 0213).

How Supplied

HOW SUPPLIED SECTION

  • Cetacaine Spray, 20 g bottle, including propellant1 (Item # 0220, NDC 10223-0201-3) which includes one cannula.
  • Cetacaine Spray Single Patient Use, 5 g bottle, including propellant1 (Item # 0222, NDC 10223-0201-4) which includes one cannula.
  • Cetacaine Liquid Chairside Kit (Item # 0218 NDC 10223-0202-6) which includes one 14 g bottle of Cetacaine Liquid with Luer-lock dispenser cap, 20 syringes and 20 delivery tips.
  • Cetacaine Liquid Clinical Kit (Item # 0212, NDC 10223-0202-5) which includes one 30 g bottle of Cetacaine Liquid with Luer-lock dispenser cap, 100 syringes and 100 delivery tips.
  • Cetacaine Liquid, 14 g bottle (Item # 0203, NDC 10223-0202-2) with Luer-lock dispenser cap.
  • Cetacaine Liquid, 30 g bottle (Item # 0211, NDC 10223-0202-4) with Luer-lock dispenser cap.

1 WARNING
Cetacaine Spray contains CFC-114 and CFC-11, substances which harm public health and environment by destroying ozone in the upper atmosphere. The propellant leak rate of Cetacaine Spray does not meet the USP requirements.

SPL UNCLASSIFIED SECTION

Made in USA

Cetylite Industries, Inc.
Pennsauken, NJ 08110

Rev. 10 /18

www.cetylite.com

PRINCIPAL DISPLAY PANEL - 11 g Bottle Box

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 10223-0202-7
Item No. 0223

Cetacaine®
Topical Anesthetic
LIQUID

With Luer-lock
Dispenser Cap

11g

Control Pain
Effective Only on
Mucous Membrane

CETYLITE®

PRINCIPAL DISPLAY PANEL - 11 g Bottle Box
PRINCIPAL DISPLAY PANEL - 11 g Bottle Box

PRINCIPAL DISPLAY PANEL - 24 g Bottle Box

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 10223-0202-8
Item No. 0224

Cetacaine®
Topical Anesthetic
LIQUID

With Luer-lock
Dispenser Cap

24g

Control Pain
Effective Only on
Mucous Membrane

CETYLITE®

PRINCIPAL DISPLAY PANEL - 24 g Bottle Box
PRINCIPAL DISPLAY PANEL - 24 g Bottle Box

PRINCIPAL DISPLAY PANEL - 11 g Bottle Kit

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

OPEN HERE

Cetacaine®

Topical Anesthetic

LIQUID

(Benzocaine 14.0%, Butamben 2.0%, and Tetracaine Hydrochloride 2.0%)

Chairside Kit

CETYLITE®

PRINCIPAL DISPLAY PANEL - 11 g Bottle Kit
PRINCIPAL DISPLAY PANEL - 11 g Bottle Kit

PRINCIPAL DISPLAY PANEL - 24 g Bottle Kit

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 10223-0226-1
ITEM NO: 0226

Cetacaine®
TOPICAL ANESTHETIC LIQUID CLINICAL KIT
(Benzocaine 14.0%, Butamben 2.0%, and Tetracaine HCl 2.0%)

Featuring a Unique Dispenser Cap for Accurate Filling of Luer-lock Syringes

KIT CONTAINS:

1 24g bottle of Cetacaine Liquid

1 Luer-lock dispenser cap

100 Microcapillary Delivery Tips

100 Delivery Syringes

CETYLITE®

Rx Only

CAUTION: Not for injection. Do not use on the eyes. Keep out of reach of children.

PRINCIPAL DISPLAY PANEL - 24 g Bottle Kit
PRINCIPAL DISPLAY PANEL - 24 g Bottle Kit

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
543786benzocaine 14 % / butamben 2 % / tetracaine HCl 2 % Mucous Membrane Topical SolutionPSN9
543789Cetacaine LIQUID 14 % / 2 % / 2 % Mucous Membrane Topical SolutionPSN9
543789benzocaine 140 MG/ML / butamben 20 MG/ML / tetracaine 20 MG/ML Mucous Membrane Topical Solution [Cetacaine]SBD9
543786benzocaine 140 MG/ML / butamben 20 MG/ML / tetracaine 20 MG/ML Mucous Membrane Topical SolutionSCD9
543786benzocaine 14 % / butamben 2 % / tetracaine HCl 2 % Mucous Membrane Topical SolutionSY9
543789Cetacaine (benzocaine 14 % / butamben 2 % / tetracaine 2 % ) Mucous Membrane Topical SolutionSY9
543789Cetacaine (benzocaine 140 MG/ML / butamben 20 MG/ML / tetracaine 20 MG/ML) Mucous Membrane Topical SolutionSY9

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
BENZOCAINE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813
TETRACAINE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
a26f29b9-6919-4f09-a354-491df8d2b97dProduct name120251021
122d1fa8-7b9e-49b4-89ce-b062ffd1d947Product name120181030
a993dfc5-f219-4460-bde6-30dd724d9ef0Product name120160818
4d7ae718-ed00-bae8-2abe-9eaec1eef7ffProduct name120140508
9137811f-f279-8640-5aeb-99fa2145d64dProduct name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
10223-0202-2Cetacaine Anesthetic1 in 1 BOXSOLUTION19
10223-0202-2Cetacaine Anesthetic14 g in 1 BOTTLE, GLASSSOLUTION149
10223-0202-4Cetacaine Anesthetic1 in 1 BOXSOLUTION19
10223-0202-4Cetacaine Anesthetic30 g in 1 BOTTLE, GLASSSOLUTION309
10223-0202-5Cetacaine Anesthetic30 g in 1 BOTTLE, GLASSSOLUTION309
10223-0202-5Cetacaine Anesthetic1 in 1 KITSOLUTION19
10223-0202-6Cetacaine Anesthetic1 in 1 KITSOLUTION19
10223-0202-6Cetacaine Anesthetic14 g in 1 BOTTLE, GLASSSOLUTION149
10223-0202-7Cetacaine Anesthetic11 g in 1 BOTTLE, GLASSSOLUTION119
10223-0202-7Cetacaine Anesthetic1 in 1 BOXSOLUTION19
10223-0202-8Cetacaine Anesthetic1 in 1 BOXSOLUTION19
10223-0202-8Cetacaine Anesthetic24 g in 1 BOTTLE, GLASSSOLUTION249
10223-0225-1Cetacaine Anesthetic11 g in 1 BOTTLE, GLASSSOLUTION119
10223-0225-1Cetacaine Anesthetic1 in 1 KITSOLUTION19
10223-0226-1Cetacaine Anesthetic24 g in 1 BOTTLE, GLASSSOLUTION249
10223-0226-1Cetacaine Anesthetic1 in 1 KITSOLUTION19

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
10223-0202CETACAINE ANESTHETIC (BENZOCAINE, BUTAMBEN, AND TETRACAINE HYDROCHLORIDE) SOLUTION [CETYLITE INDUSTRIES, INC.]9Current NDC, Legacy NDC, 12 package rows20250116_89f262a4-a41b-41d7-806b-61b9b89542f0.zip
10223-0225CETACAINE ANESTHETIC (BENZOCAINE, BUTAMBEN, AND TETRACAINE HYDROCHLORIDE) SOLUTION [CETYLITE INDUSTRIES, INC.]9Current NDC, 2 package rows20250116_89f262a4-a41b-41d7-806b-61b9b89542f0.zip
10223-0226CETACAINE ANESTHETIC (BENZOCAINE, BUTAMBEN, AND TETRACAINE HYDROCHLORIDE) SOLUTION [CETYLITE INDUSTRIES, INC.]9Current NDC, 2 package rows20250116_89f262a4-a41b-41d7-806b-61b9b89542f0.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
10223-0202-2GM - Gram10223-0202abdc1d13-bab9-406a-a562-617ef0a9398912012-07-24
10223-0202-3GM - Gram10223-02026fd1486d-070d-4c77-a1bb-09ca413b7d3312012-07-24
10223-0202-4GM - Gram10223-020230f907fc-0f89-47c1-ab73-070e492c7c6512012-07-24
10223-0202-5GM - Gram10223-0202f5bfe00b-444e-45a8-86ff-ac9f2eb9651c12019-08-06

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
BenzocaineACTIVE INGREDIENTU3RSY48JW54
ButambenACTIVE INGREDIENTEFW857872Q4
Tetracaine HydrochlorideACTIVE INGREDIENT5NF5D4OPCI4
BenzocaineACTIVE MOIETYU3RSY48JW54
ButambenACTIVE MOIETYEFW857872Q4
TetracaineACTIVE MOIETY0619F35CGV4
Benzalkonium chlorideINACTIVE INGREDIENTF5UM2KM3W74
Dipropylene glycolINACTIVE INGREDIENTE107L85C404
Mecetronium BromideINACTIVE INGREDIENT7ZNQ7FIO9K4
SaccharinINACTIVE INGREDIENTFST467XS7D4

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 10 matching rows.

NDC Codes#

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 21 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 2 · 66 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
Dipropylene glycolDIPROPYLENE GLYCOLE107L85C40FILM, EXTENDED RELEASE / TRANSDERMAL296 mgExact identifier — unii candidate
33 equally ranked IID candidates
SaccharinSACCHARINFST467XS7DSOLUTION / ORAL150 mgExact identifier — unii+dosage form
22 equally ranked IID candidates
SaccharinSACCHARINFST467XS7DSOLUTION / ORAL150 mgExact identifier — unii+dosage form
22 equally ranked IID candidates
Benzalkonium chlorideBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION / TOPICAL0.02 %w/vExact identifier — unii+route+dosage form
11 equally ranked IID candidates
SaccharinSACCHARINFST467XS7DSOLUTION / ORAL150 mgExact identifier — unii+dosage form
22 equally ranked IID candidates
SaccharinSACCHARINFST467XS7DOINTMENT / TOPICAL0.5 %w/wExact identifier — unii+route
22 equally ranked IID candidates
Dipropylene glycolDIPROPYLENE GLYCOLE107L85C40FILM, EXTENDED RELEASE / BUCCAL30 mgExact identifier — unii candidate
33 equally ranked IID candidates
Benzalkonium chlorideBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION / TOPICAL0.02 %w/vExact identifier — unii+route+dosage form
11 equally ranked IID candidates
Dipropylene glycolDIPROPYLENE GLYCOLE107L85C40FILM, EXTENDED RELEASE / BUCCAL30 mgExact identifier — unii candidate
33 equally ranked IID candidates
Dipropylene glycolDIPROPYLENE GLYCOLE107L85C40FILM, EXTENDED RELEASE / TRANSDERMAL296 mgExact identifier — unii candidate
33 equally ranked IID candidates
Dipropylene glycolDIPROPYLENE GLYCOLE107L85C40SYSTEM / TRANSDERMAL6 mgExact identifier — unii candidate
33 equally ranked IID candidates
Dipropylene glycolDIPROPYLENE GLYCOLE107L85C40FILM, EXTENDED RELEASE / TRANSDERMAL296 mgExact identifier — unii candidate
33 equally ranked IID candidates
Benzalkonium chlorideBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION / TOPICAL0.02 %w/vExact identifier — unii+route+dosage form
11 equally ranked IID candidates
Dipropylene glycolDIPROPYLENE GLYCOLE107L85C40SYSTEM / TRANSDERMAL6 mgExact identifier — unii candidate
33 equally ranked IID candidates
Dipropylene glycolDIPROPYLENE GLYCOLE107L85C40SYSTEM / TRANSDERMAL6 mgExact identifier — unii candidate
33 equally ranked IID candidates
Dipropylene glycolDIPROPYLENE GLYCOLE107L85C40SYSTEM / TRANSDERMAL6 mgExact identifier — unii candidate
33 equally ranked IID candidates
Benzalkonium chlorideBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION / TOPICAL0.02 %w/vExact identifier — unii+route+dosage form
11 equally ranked IID candidates
SaccharinSACCHARINFST467XS7DSOLUTION / ORAL150 mgExact identifier — unii+dosage form
22 equally ranked IID candidates
Benzalkonium chlorideBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION / TOPICAL0.02 %w/vExact identifier — unii+route+dosage form
11 equally ranked IID candidates
SaccharinSACCHARINFST467XS7DOINTMENT / TOPICAL0.5 %w/wExact identifier — unii+route
22 equally ranked IID candidates
Dipropylene glycolDIPROPYLENE GLYCOLE107L85C40SYSTEM / TRANSDERMAL6 mgExact identifier — unii candidate
33 equally ranked IID candidates
SaccharinSACCHARINFST467XS7DOINTMENT / TOPICAL0.5 %w/wExact identifier — unii+route
22 equally ranked IID candidates
SaccharinSACCHARINFST467XS7DOINTMENT / TOPICAL0.5 %w/wExact identifier — unii+route
22 equally ranked IID candidates
Dipropylene glycolDIPROPYLENE GLYCOLE107L85C40FILM, EXTENDED RELEASE / BUCCAL30 mgExact identifier — unii candidate
33 equally ranked IID candidates
Dipropylene glycolDIPROPYLENE GLYCOLE107L85C40SYSTEM / TRANSDERMAL6 mgExact identifier — unii candidate
33 equally ranked IID candidates
SaccharinSACCHARINFST467XS7DSOLUTION / ORAL150 mgExact identifier — unii+dosage form
22 equally ranked IID candidates
SaccharinSACCHARINFST467XS7DOINTMENT / TOPICAL0.5 %w/wExact identifier — unii+route
22 equally ranked IID candidates
SaccharinSACCHARINFST467XS7DSOLUTION / ORAL150 mgExact identifier — unii+dosage form
22 equally ranked IID candidates
Dipropylene glycolDIPROPYLENE GLYCOLE107L85C40FILM, EXTENDED RELEASE / TRANSDERMAL296 mgExact identifier — unii candidate
33 equally ranked IID candidates
Dipropylene glycolDIPROPYLENE GLYCOLE107L85C40SYSTEM / TRANSDERMAL6 mgExact identifier — unii candidate
33 equally ranked IID candidates
Benzalkonium chlorideBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION / TOPICAL0.02 %w/vExact identifier — unii+route+dosage form
11 equally ranked IID candidates
Dipropylene glycolDIPROPYLENE GLYCOLE107L85C40FILM, EXTENDED RELEASE / BUCCAL30 mgExact identifier — unii candidate
33 equally ranked IID candidates
Dipropylene glycolDIPROPYLENE GLYCOLE107L85C40SYSTEM / TRANSDERMAL6 mgExact identifier — unii candidate
33 equally ranked IID candidates
Dipropylene glycolDIPROPYLENE GLYCOLE107L85C40FILM, EXTENDED RELEASE / BUCCAL30 mgExact identifier — unii candidate
33 equally ranked IID candidates
Dipropylene glycolDIPROPYLENE GLYCOLE107L85C40FILM, EXTENDED RELEASE / TRANSDERMAL296 mgExact identifier — unii candidate
33 equally ranked IID candidates
SaccharinSACCHARINFST467XS7DOINTMENT / TOPICAL0.5 %w/wExact identifier — unii+route
22 equally ranked IID candidates
SaccharinSACCHARINFST467XS7DSOLUTION / ORAL150 mgExact identifier — unii+dosage form
22 equally ranked IID candidates
SaccharinSACCHARINFST467XS7DSOLUTION / ORAL150 mgExact identifier — unii+dosage form
22 equally ranked IID candidates
Dipropylene glycolDIPROPYLENE GLYCOLE107L85C40FILM, EXTENDED RELEASE / BUCCAL30 mgExact identifier — unii candidate
33 equally ranked IID candidates
SaccharinSACCHARINFST467XS7DSOLUTION / ORAL150 mgExact identifier — unii+dosage form
22 equally ranked IID candidates
Benzalkonium chlorideBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION / TOPICAL0.02 %w/vExact identifier — unii+route+dosage form
11 equally ranked IID candidates
Dipropylene glycolDIPROPYLENE GLYCOLE107L85C40SYSTEM / TRANSDERMAL6 mgExact identifier — unii candidate
33 equally ranked IID candidates
SaccharinSACCHARINFST467XS7DSOLUTION / ORAL150 mgExact identifier — unii+dosage form
22 equally ranked IID candidates
Benzalkonium chlorideBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION / TOPICAL0.02 %w/vExact identifier — unii+route+dosage form
11 equally ranked IID candidates
Benzalkonium chlorideBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION / TOPICAL0.02 %w/vExact identifier — unii+route+dosage form
11 equally ranked IID candidates
Dipropylene glycolDIPROPYLENE GLYCOLE107L85C40FILM, EXTENDED RELEASE / BUCCAL30 mgExact identifier — unii candidate
33 equally ranked IID candidates
Dipropylene glycolDIPROPYLENE GLYCOLE107L85C40FILM, EXTENDED RELEASE / TRANSDERMAL296 mgExact identifier — unii candidate
33 equally ranked IID candidates
Dipropylene glycolDIPROPYLENE GLYCOLE107L85C40FILM, EXTENDED RELEASE / BUCCAL30 mgExact identifier — unii candidate
33 equally ranked IID candidates
Dipropylene glycolDIPROPYLENE GLYCOLE107L85C40FILM, EXTENDED RELEASE / TRANSDERMAL296 mgExact identifier — unii candidate
33 equally ranked IID candidates
SaccharinSACCHARINFST467XS7DOINTMENT / TOPICAL0.5 %w/wExact identifier — unii+route
22 equally ranked IID candidates
Dipropylene glycolDIPROPYLENE GLYCOLE107L85C40FILM, EXTENDED RELEASE / BUCCAL30 mgExact identifier — unii candidate
33 equally ranked IID candidates
SaccharinSACCHARINFST467XS7DOINTMENT / TOPICAL0.5 %w/wExact identifier — unii+route
22 equally ranked IID candidates
SaccharinSACCHARINFST467XS7DSOLUTION / ORAL150 mgExact identifier — unii+dosage form
22 equally ranked IID candidates
SaccharinSACCHARINFST467XS7DOINTMENT / TOPICAL0.5 %w/wExact identifier — unii+route
22 equally ranked IID candidates
Dipropylene glycolDIPROPYLENE GLYCOLE107L85C40FILM, EXTENDED RELEASE / TRANSDERMAL296 mgExact identifier — unii candidate
33 equally ranked IID candidates
SaccharinSACCHARINFST467XS7DOINTMENT / TOPICAL0.5 %w/wExact identifier — unii+route
22 equally ranked IID candidates
SaccharinSACCHARINFST467XS7DOINTMENT / TOPICAL0.5 %w/wExact identifier — unii+route
22 equally ranked IID candidates
Dipropylene glycolDIPROPYLENE GLYCOLE107L85C40FILM, EXTENDED RELEASE / TRANSDERMAL296 mgExact identifier — unii candidate
33 equally ranked IID candidates
Dipropylene glycolDIPROPYLENE GLYCOLE107L85C40FILM, EXTENDED RELEASE / TRANSDERMAL296 mgExact identifier — unii candidate
33 equally ranked IID candidates
Dipropylene glycolDIPROPYLENE GLYCOLE107L85C40FILM, EXTENDED RELEASE / BUCCAL30 mgExact identifier — unii candidate
33 equally ranked IID candidates

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Cetacaine AnestheticBENZOCAINE, BUTAMBEN, AND TETRACAINE HYDROCHLORIDECetylite Industries, Inc.89f262a4-a41b-41d7-806b-61b9b89542f02025-01-10WarningsExact identifier
ndc (package): 10223-0202-4
ndc (package): 10223-0225-1
ndc (package): 10223-0202-5
ndc (package): 10223-0226-1
ndc (package): 10223-0202-2
ndc (package): 10223-0202-6
ndc (package): 10223-0202-7
ndc (package): 10223-0202-8
ndc (product): 10223-0226
ndc (product): 10223-0225
ndc (product): 10223-0202
ndc11 (package): 10223020206
ndc11 (package): 10223020207
ndc11 (package): 10223022601
ndc11 (package): 10223020202
ndc11 (package): 10223022501
ndc11 (package): 10223020204
ndc11 (package): 10223020208
ndc11 (package): 10223020205
spl id: 66344c64-2439-4a34-8eb4-707e707c8ab1
spl set id: 89f262a4-a41b-41d7-806b-61b9b89542f0

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.